DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
1st article in the last 90 days, the first article referencing Beckman Coulter Diagnostics.
Companies mentioned
Best suited for
- Decision stage
- Which to buy
- Adoption curve
- Innovators
Our classification, not the publisher's statement. Best suited for, not only for.
Diagnos Inc. announced plans to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026. This decision is contingent on approval from the TSX Venture Exchange. The warrants were issued as part of a non-brokered private placement initially announced on May 9, 2024.
The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended exercise period. Diagnos stated that it will issue a follow-up release if the Exchange rejects its application for this amendment.
Diagnos specializes in early detection of eye-related health issues through the use of advanced technology and Artificial Intelligence (AI). Its aim is to provide clinicians with enhanced diagnostic capabilities and improve patient outcomes.
Press release, provided by Globe Newswire on behalf of Beckman Coulter Diagnostics. Read the original.